Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.…
Rein reports early Phase II data for inhaled IPF drug
Rein Therapeutics (NASDAQ: RNTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 0.3369 USD on 20 November 2026, down 78.4% over 52 weeks. Its 52-week range is 0.2844 USD to 2.100 USD: the price is 84.0% below the high and 18.5% above the low.
Its market capitalisation is 29.06M USD.
Rein Therapeutics reports return on equity of 177.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 35.49M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.